跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 27,939 条关于
“PD-L1 IHC 28-8 pharmDx”
全部
27,939
临床试验
8,925
药物
3,558
机构
7,246
资讯
8,210
去年
Agilent's PD-L1 IHC 28-8 pharmDx Receives EU Certification for Lung Cancer and Melanoma Diagnostics
26年前
FDA Approves Pembrolizumab for Advanced Esophageal Squamous Cell Cancer with PD-L1 Expression
去年
Agilent's MMR IHC Panel PharmDx Receives FDA Approval as Companion Diagnostic for Colorectal Cancer Immunotherapy
去年
Advancements in PD-L1 Immunohistochemistry and Digital Pathology
2年前
Adjuvant PD-1/PD-L1 Inhibitors Don't Improve Survival in Resectable NSCLC
13年前
European Market Access Hurdles Loom for PD-1/PD-L1 Immunotherapies in Oncology
去年
Phase 3 Trials Advance PD-1/PD-L1 Inhibitors for BCG-Naive NMIBC
去年
PD-1/PD-L1 Inhibitors Plus Chemotherapy Shows Improved Outcomes in Asian TNBC Patients
去年
PD-1/PD-L1 Inhibitors Show Promise in Thyroid Cancer Treatment Through Combination Strategies
去年
PD-L1 Expression Correlates with HRD Status and Predicts Survival in High-Grade Serous Ovarian Cancer
第 1 页,共 821 页
上一页
下一页